Trial Profile

Open-Label Extension, Phase 2b Study to Evaluate the Longer Term Efficacy and Safety of LIB003 in Patients on Stable Lipid Lowering Therapy Requiring Additional LDL-C Reduction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lerodalcibep (Primary)
Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
Focus Adverse reactions
Sponsors LIB Therapeutics

Most Recent Events

01 Nov 2020 Status changed from active, no longer recruiting to completed.
21 Apr 2020 Planned End Date changed from 31 Mar 2020 to 31 May 2020.
30 Mar 2020 Results (n=29) of 32 weeks of safety and efficacy presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com